AstraZeneca Finds Increased Hemoglobinin in Roxadustat Phase 3 Trial

Date : 11/08/2019 @ 7:48AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7878.0  171.0 (2.22%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Finds Increased Hemoglobinin in Roxadustat Phase 3 Trial

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Astrazeneca Charts.

By Adriano Marchese


AstraZeneca PLC (AZN.LN) said Friday that its drug Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in Phase 3 Olympus and Rockies trials.

The drugmaker said the results of the global Phase 3 program as well as other data will form part of a regulatory submission in the U.S., which is anticipated in the fourth quarter of 2019.

Roxadustat is currently approved in China for the treatment of anemia in patients with CKD, regardless of whether they require dialysis, the company said.


Write to Adriano Marchese at


(END) Dow Jones Newswires

November 08, 2019 02:33 ET (07:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200117 20:02:30